Specialists Detail After-Vaccine Dangers and Conduct Risk-Benefit Assessment
AstraZeneca, a leading global pharmaceutical company, has acknowledged a rare side effect associated with its Covid-19 vaccine, developed in collaboration with Oxford University. This side effect involves blood clotting and low platelet count following immunization. In India, where the vaccine is known as Covishield and produced by the Serum Institute of India in Pune, it has been widely administered, totaling 1.75 billion doses. This revelation understandably prompts concerns about the safety of the vaccine that millions have received. The acknowledgment by AstraZeneca underscores the importance of ongoing vigilance and assessment of vaccine safety, particularly regarding rare adverse events. As experts continue to analyze the risk-benefit profile of the vaccine, transparent communication and thorough monitoring are vital to ensure public trust and confidence in vaccination efforts.
As per The Daily Telegraph, AstraZeneca disclosed the side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS) during a legal proceeding where it faces allegations of severe harm and fatalities linked to the vaccine. Although this marks the company’s initial acknowledgment in a courtroom setting, TTS has been extensively documented and recognized in scientific research. Reports of TTS emerged shortly after the commencement of vaccination campaigns in Europe, prompting temporary suspensions of the AstraZeneca vaccine in certain countries. These events underscore the importance of ongoing scrutiny and transparency in assessing vaccine safety and addressing emerging concerns.
AstraZeneca Acknowledges Clotting Risk in its Vaccine: Why Indian Covishield Vaccine Recipients Need Not Panic
What Implications Does the Case Hold for Covishield Recipients in India?
In the inaugural year of Covid-19 vaccination in India, the Government committee on Adverse Events Following Immunisation (AEFI) examined at least 36 cases of Thrombosis with Thrombocytopenia Syndrome (TTS), confirming 18 related deaths in 2021. However, Indian citizens affected by this syndrome encounter hurdles in joining the British petition. Legal barriers, such as differences in regulatory approvals and the vaccine’s production by an Indian manufacturer under local jurisdiction, impede their participation. Thus, despite Indian health authorities acknowledging TTS cases, negotiating these legal complexities may restrict affected individuals from directly engaging in international legal actions.
Why Not to Panic ?
- Experts note that Thrombosis with Thrombocytopenia Syndrome (TTS) was promptly reported by European nations during the early stages of the pandemic, yet its occurrence in India remained exceedingly rare. According to a senior health ministry official involved in vaccination strategy discussions, “TTS is an exceptionally uncommon side effect, particularly among Indians and South Asians when compared to Europeans. However, ample evidence suggests that vaccination has been instrumental in saving lives—its benefits far surpass the associated risks.” This perspective underscores the importance of vaccination efforts despite rare adverse events, emphasizing the overall positive impact of immunization on public health.
- Moreover, not only is the risk rare, but it’s most prominent in the initial weeks post the first vaccination dose. With the majority of Indians now having received three doses and a considerable time having elapsed since, the risk significantly decreases. Dr. Gagandeep Kang, Director of Global Health at the Bill and Melinda Gates Foundation and a member of the WHO safety advisory committee for COVID-19 vaccines, stresses the importance of reassuring individuals regarding the timing of Thrombosis with Thrombocytopenia Syndrome (TTS) occurrence. “It’s critical to convey that TTS incidents mainly occur shortly after vaccination. We’re well past the vaccination phase,” she asserts. This perspective highlights the diminishing relevance of TTS risk for vaccinated individuals.
- People’s current reactions are surprising. Even during the vaccination campaigns, the rare side effect was thoroughly documented and scientifically acknowledged,” comments Dr. Anurag Agarwal, Dean of Biosciences and Health Research at the Trivedi School of Biosciences, Ashoka University. “The benefits of vaccination during the pandemic peak far outweighed the associated risks,” he emphasizes.
- Additionally, the package insert for Covishield consistently included a cautionary note about the rare condition. It stated, “A very rare and serious (side effect) … has been observed following vaccination with ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) during post-authorisation use… Cases have occurred in patients with a previous history of thrombosis, as well as in patients with autoimmune disorders. The benefits and risks of vaccination should be considered in these patients.”
- In a study published in Lancet Global Health in 2022, it was revealed that AstraZeneca had documented rates of 8.1 cases of Thrombosis with Thrombocytopenia Syndrome (TTS) per million individuals receiving the first dose and 2.3 cases per million for the second dose. Furthermore, the study highlighted regional disparities in TTS reporting, with Nordic countries exhibiting the highest incidence at 17.6 cases per million doses, while Asian countries reported the lowest incidence at 0.2 cases per million doses.
Final Thoughts
While AstraZeneca’s acknowledgment of the clotting risk associated with its vaccine may raise concerns among Covishield recipients in India, it’s important to maintain perspective. The rarity of adverse events, coupled with the significant benefits of vaccination in combating the COVID-19 pandemic, underscores the importance of informed decision-making. Furthermore, regulatory agencies and health experts continue to monitor vaccine safety closely. Covishield recipients can take solace in the fact that the risk of severe outcomes is minimal, especially given the extensive vaccination coverage and the passage of time since initial doses. Vigilance, trust in scientific evidence, and transparent communication remain paramount.
Also read: 8 Most Revolutionary Medical Inventions That Transformed Healthcare Globally
